Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
MSI-H Cancer: early-phase trial registry
2 of 4 indexed MSI-H Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
MSI-H Cancer: 4 US clinical trials tracked, 2 recruiting.
MSI-H Cancer is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is 23andMe, running 1 of these trials.
Enrollment posture brief
Registry condition msi-h-cancer
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
MSI-H Cancer lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for MSI-H Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
MSI-H Cancer is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Wadjet
NCT06898450
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06974110
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics
NCT05651022
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on MSI-H Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on MSI-H Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this MSI-H Cancer page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 MSI-H Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- 23andMe sponsors the most MSI-H Cancer trials on record, review their full trial history before evaluating a specific study. See 23andMe's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MSI-H Cancer condition card totals 4 registered trials; most-linked intervention 23ME-00610; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.